safety;malignant lymphoma;
Showing 1 - 25 of >10,000
Marginal Zone Lymphoma Trial ([68Ga]Ga-PentixaFor, [18F]Fluorodeoxyglucose)
Not yet recruiting
- Marginal Zone Lymphoma
- (no location specified)
Nov 6, 2023
Lymphoma Trial in Hangzhou (Autologous hematopoietic stem cell transplantation combined with CD19 CAR-T cells)
Recruiting
- Lymphoma
- Autologous hematopoietic stem cell transplantation combined with CD19 CAR-T cells
-
Hangzhou, Zhejiang, ChinaThe first affiliated hospital of medical college of zhejiang uni
Feb 13, 2022
Advanced Solid Tumor, Relapsed/Refractory Lymphoma Trial in Beijing (OVV-01 Injection+IBR900 Cell Injection)
Recruiting
- Advanced Solid Tumor
- Relapsed/Refractory Lymphoma
- OVV-01 Injection+IBR900 Cell Injection
-
Beijing, Beijing, ChinaBeijing Boren Hospital
Mar 4, 2022
Microsatellite High Cancers, Peritoneal Mesothelioma, Extrapulmonary High Grade Trial in Houston (XmAb20717)
Recruiting
- Microsatellite High Cancers
- +7 more
-
Houston, TexasM D Anderson Cancer Center
Aug 8, 2022
Acute Lymphoblastic Leukemia, Myeloblastic Leukemia, Biphenotypic Acute Leukemia Trial (GVHD prevention: post-transplantation
Not yet recruiting
- Acute Lymphoblastic Leukemia
- +5 more
- GVHD prevention: post-transplantation cyclophosphamide, abatacept, vedolizumab, calcineurin inhibitor
- (no location specified)
Aug 23, 2022
Acute Myeloid Leukemia, Non-hodgkin's Lymphoma, Multiple Myeloma Trial in Hangzhou (CD70 CAR T-cells)
Recruiting
- Acute Myeloid Leukemia
- +2 more
- CD70 CAR T-cells
-
Hangzhou, Zhejiang, ChinaThe first affiliated hospital of medical college of zhejiang uni
Oct 26, 2021
Pediatric Solid Tumor, Pediatric Lymphoma, Pediatric Brain Tumor Trial in Australia, Canada, United States (CLR 131)
Recruiting
- Pediatric Solid Tumor
- +7 more
- CLR 131
-
Palo Alto, California
- +6 more
Nov 30, 2021
Mucopolysaccharidosis I, Mucopolysaccharidosis VI, Adrenoleukodystrophy Trial in Denver, Valhalla, Salt Lake City (Human
Completed
- Mucopolysaccharidosis I
- +15 more
- Human Placental Derived Stem Cell
-
Denver, Colorado
- +2 more
Oct 24, 2022
Malignant Lymphoma, Multiple Myeloma Trial (Pentaisomaltose)
Not yet recruiting
- Malignant Lymphoma
- Multiple Myeloma
- Pentaisomaltose
- (no location specified)
Jan 5, 2023
Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer Trial in United Kingdom (NX-1607)
Recruiting
- Ovarian Cancer, Epithelial
- +14 more
-
Sutton, Surrey, United Kingdom
- +6 more
Jul 22, 2022
Relapsed or Refractory Non-Hodgkin's Lymphoma, Relapsed or Refractory Multiple Myeloma Trial in Changsha (BEBT-908 for
Completed
- Relapsed or Refractory Non-Hodgkin's Lymphoma
- Relapsed or Refractory Multiple Myeloma
- BEBT-908 for injection
-
Changsha, Hunan, ChinaHunan Cancer Hospital
Oct 9, 2023
Aggressive Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma, Locally Advanced Malignant Solid Tumor Trial run by the NCI (p97
Withdrawn
- Aggressive Non-Hodgkin Lymphoma
- +3 more
- p97 Inhibitor CB-5339 Tosylate
-
Bethesda, Maryland
- +1 more
Aug 27, 2021
COVID-19 Infection in Malignant Lymphomas Participating in
Completed
- Malignant Lymphoma
- +2 more
- No intervention
-
Guangzhou, Guangdong, ChinaDepartment of Medical Oncology, Sun Yat-Sen University Cancer Ce
Apr 22, 2023
Recurrent/Refractory Malignant Lymphoma Trial in Beijing (JS004 , Recombinant humanized IgG4k mAb specific to BTLA for injection
Recruiting
- Recurrent/Refractory Malignant Lymphoma
- JS004 , Recombinant humanized IgG4k monoclonal antibody specific to BTLA for injection Intravenous infusion
- Drug：JS001, Intravenous infusion
-
Beijing, Beijing, ChinaBeijing Cancer Hospital
Apr 13, 2022
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Juvenile Myelomonocytic Leukemia Trial (Miltenyi CliniMACS Prodigy ®
Not yet recruiting
- Acute Lymphoblastic Leukemia
- +6 more
- Miltenyi CliniMACS Prodigy ® system
- (no location specified)
Mar 23, 2023
DLBCL Trial (Polatuzumab Vedotin)
Not yet recruiting
- Diffuse Large B-Cell Lymphoma
- Polatuzumab Vedotin
- (no location specified)
Jul 12, 2023
Malignant Lymphoma Trial in Tianjin (Toripalimab)
Completed
- Malignant Lymphoma
- Toripalimab
-
Tianjin, Tianjin, ChinaBlood Diseases Hospital, Chinese Academy of Medical Sciences
Sep 28, 2020
Relapsed or Refractory B-cell Lymphoma Trial in Guangzhou (infusion of JY231 injection)
Recruiting
- Relapsed or Refractory B-cell Lymphoma
- infusion of JY231 injection
-
Guangzhou, Guangdong, ChinaGuangdong Second Provincial General Hospital
Sep 17, 2023
Advanced Malignant Tumors Trial (AK127 Q3W IV infusion ,AK104 10mg/kg Q3W IV infusion)
Not yet recruiting
- Advanced Malignant Tumors
- AK127 Q3W IV infusion ,AK104 10mg/kg Q3W IV infusion
- (no location specified)
May 11, 2023
Lymphoma, B-Cell, Leukemia, B-cell, Leukemia, T-Cell Trial in Cangzhou (CAR-T)
Recruiting
- Lymphoma, B-Cell
- +3 more
- CAR-T
-
Cangzhou, Hebei, ChinaCangzhou People's Hospital
Nov 9, 2022
Advanced Cancer, Advanced Solid Tumor, Tumor Malignant Trial in United Kingdom (Fosifloxuridine Nafalbenamide, Leucovorin,
Not yet recruiting
- Advanced Cancer
- +16 more
- Fosifloxuridine Nafalbenamide
- +3 more
-
Birmingham, United Kingdom
- +3 more
Feb 1, 2023
Advanced Lymphoma, Advanced Malignant Solid Tumor, Advanced Pancreatic Carcinoma Trial in New Haven (BET Bromodomain Inhibitor
Recruiting
- Advanced Lymphoma
- +13 more
- BET Bromodomain Inhibitor ZEN-3694
- +2 more
-
New Haven, ConnecticutYale University Cancer Center LAO
Jun 29, 2022